Fredun Pharmaceuticals Limited , a prominent player in the pharmaceutical sector, has announced a significant change in its corporate structure. Parag Goyal, who has been serving as the Company Secretary and Compliance Officer, is set to resign from his position.

Key Details of the Resignation

• Effective Date: Parag Goyal's resignation will take effect from the close of working hours on November 26, 2025.
• Reason: The resignation has been attributed to personal commitments.
• Acceptance: The Board of Directors has accepted Goyal's resignation.

Company's Response

Fredun Pharmaceuticals has stated that it will inform the stock exchanges once a new Company Secretary and Compliance Officer is appointed. This move ensures transparency and compliance with regulatory requirements.

Acknowledgment

In his resignation letter, Parag Goyal expressed gratitude for the opportunity to serve Fredun Pharmaceuticals Limited. He acknowledged the trust, support, and cooperation extended to him by all members of the Board during his tenure.

Regulatory Compliance

The company has duly informed the BSE Ltd. about this development, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Fredun Pharmaceuticals has also provided the necessary details as required under these regulations.

Financial Performance Context

While this corporate change is taking place, it's worth noting that Fredun Pharmaceuticals has recently reported its financial results for the quarter and half-year ended September 30, 2025. The Board of Directors approved these unaudited financial results in a meeting held on November 8, 2025.

This corporate governance update comes at a time when the company has shown strong financial performance, with a significant increase in net sales and profitability compared to the previous year.

As Fredun Pharmaceuticals navigates this transition in its key compliance role, stakeholders will be watching for the appointment of a new Company Secretary and Compliance Officer to ensure continued adherence to regulatory standards and smooth corporate operations.

Fredun Pharmaceuticals Limited, a pharmaceutical company based in Maharashtra, has reported a significant increase in its financial performance for the quarter ended September 30, 2025. The company's unaudited financial results, approved by the Board of Directors on November 8, 2025, reveal substantial growth in both revenue and profitability.

Financial Highlights

The company's performance shows a remarkable improvement across key financial metrics:

• Net Profit: Jumped by 128% to ₹9.73 crore, compared to ₹4.27 crore in the same quarter last year.
• Revenue: Increased by 45% to ₹149.59 crore from ₹102.99 crore year-on-year.
• Earnings Per Share (EPS): More than doubled to ₹20.61 from ₹9.05 in the corresponding quarter.

Half-Year Performance

For the half-year period, Fredun Pharmaceuticals reported a net profit of ₹16.50 crore, up from ₹8.40 crore in the previous comparable period, marking a significant improvement in the company's financial health.

Company Overview

Fredun Pharmaceuticals Limited operates in the pharmaceutical and healthcare segment. The company's manufacturing facilities are located in Palghar, Maharashtra, positioning it strategically in one of India's key pharmaceutical hubs.

Board Meeting and Compliance

The Board of Directors convened on November 8, 2025, to approve these unaudited financial results. The meeting, which started at 4:00 p.m., concluded at 10:30 p.m., indicating a thorough review of the company's performance.

In compliance with SEBI regulations, the company had closed its trading window for insiders from October 1, 2025, until 48 hours after the declaration of the financial results, ensuring fair trading practices.

Auditor's Review

R.H. Nisar & Co., the statutory auditors, conducted a limited review of the consolidated unaudited financial results. Their review, performed in accordance with the Standard on Review Engagements (SRE) 2410, found no material misstatements in the financial information provided by the company.

The strong financial performance of Fredun Pharmaceuticals Limited in Q2 FY2026 reflects the company's robust growth trajectory in the pharmaceutical sector. These results demonstrate significant improvements in profitability and revenue amidst the current economic environment.